{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-071389","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.242751+00:00","generated_at":"2026-05-23T23:45:14.166594+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Verrica appoints Gavin Corcoran to board as Class I director","bullets":["Dr. Corcoran appointed effective March 31, 2025; term expires at 2025 annual meeting.","Granted option to purchase 17,502 shares at grant-date closing price; vests over 3 years.","Receives $40,000 annual retainer; eligible for annual option of 20,000 shares.","Currently Chief Development Officer of Formation Bio; former CMO of Allergan and Actavis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-071389","json":"https://secwatch.observer/filing/0001193125-25-071389.json","markdown":"https://secwatch.observer/filing/0001193125-25-071389.md","text":"https://secwatch.observer/filing/0001193125-25-071389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/0001193125-25-071389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/d906738d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T23:45:14.166594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c070749c8c","claim":"Gavin Corcoran was appointed as Director at Verrica Pharmaceuticals Inc..","evidence_excerpt":"On March 31, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Gavin Corcoran to serve as a director of the Company effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525071389/0001193125-25-071389-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}